|
|
|
Insider
Information: |
Foletta Mark G |
Relationship: |
EVP & Chief Financial ... |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
110,179 |
|
Indirect Shares
|
62,398 |
|
|
Direct
Value |
$1,139,767 |
|
|
Indirect Value
|
$7,947,633 |
|
|
Total
Shares |
172,577 |
|
|
Total
Value |
$9,087,400 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
1
|
Stock
price went up :
|
1
|
1
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
Percentage
Gain/Loss : |
0.7%
|
13.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Amylin Pharmaceuticals Inc |
AMLN |
SVP, Chief Financial O... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
DexCom Inc |
DXCM |
Director |
2024-05-22 |
2,973 |
2024-05-22 |
62,398 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
Director |
2017-12-04 |
81,910 |
2015-08-13 |
0 |
Premium* |
|
AMN Healthcare Services Inc |
AHS |
Director |
2024-04-19 |
10,254 |
2016-04-20 |
0 |
Premium* |
|
Forte Biosciences Inc |
FBRX |
EVP & Chief Financial ... |
2019-05-28 |
15,042 |
2017-04-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
144 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-04-30 |
4 |
AS |
$42.32 |
$105,800 |
D/D |
(2,500) |
23,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-04-30 |
4 |
OE |
$13.25 |
$33,125 |
D/D |
2,500 |
25,742 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-05-31 |
4 |
OE |
$13.25 |
$86,125 |
D/D |
6,500 |
29,742 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-05-31 |
4 |
AS |
$45.79 |
$297,663 |
D/D |
(6,500) |
23,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-06-29 |
4 |
AS |
$41.38 |
$103,455 |
D/D |
(2,500) |
23,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-06-29 |
4 |
OE |
$13.25 |
$33,125 |
D/D |
2,500 |
25,742 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-07-31 |
4 |
AS |
$47.43 |
$166,022 |
D/D |
(3,500) |
23,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-07-31 |
4 |
OE |
$13.25 |
$46,375 |
D/D |
3,500 |
26,742 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-08-31 |
4 |
OE |
$13.25 |
$39,750 |
D/D |
3,000 |
26,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-08-31 |
4 |
AS |
$48.86 |
$146,575 |
D/D |
(3,000) |
23,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-09-28 |
4 |
OE |
$13.25 |
$39,750 |
D/D |
3,000 |
26,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2007-09-28 |
4 |
AS |
$49.98 |
$149,932 |
D/D |
(3,000) |
23,242 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Senior VP, Finance & CFO |
|
2008-02-01 |
4 |
A |
$37.00 |
$6,734 |
D/D |
182 |
23,753 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Sr VP Finance & CFO |
|
2009-02-03 |
4 |
A |
$11.80 |
$6,903 |
D/D |
585 |
24,839 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
Sr VP Finance & CFO |
|
2009-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
2,550 |
3,455 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP Chief Financial Officer |
|
2010-02-03 |
4 |
A |
$17.83 |
$7,346 |
D/D |
412 |
26,412 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP Chief Financial Officer |
|
2010-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,360 |
4,815 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
|
2010-04-06 |
4 |
OE |
$13.25 |
$8,454 |
D/D |
638 |
28,138 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
|
2011-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
41,457 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
|
2011-03-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,630 |
6,445 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
|
2012-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
49,687 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
|
2012-02-08 |
4 |
D |
$16.47 |
$51,419 |
D/D |
(3,122) |
54,565 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial Officer |
|
2012-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
57,687 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
|
2012-03-01 |
4 |
S |
$17.11 |
$31,585 |
D/D |
(1,846) |
62,490 |
0 |
- |
|
AMLN |
Amylin Pharmaceuticals In... |
SVP, Chief Financial OfficerSV |
|
2012-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
72,490 |
0 |
- |
|
144 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|